Among the banned items are numerous Fixed Dose Combination (FDC) drugs — formulations that combine two or more pharmaceutical ingredients in fixed proportions.
Among the banned items are numerous Fixed Dose Combination (FDC) drugs — formulations that combine two or more pharmaceutical ingredients in fixed proportions. These so-called 'cocktail drugs' are popular in Indian markets for their convenience but often come under scrutiny for safety and efficacy concerns.
The banned list also includes:
Paracetamol-based formulations
Cough syrups
Antihistamines
A batch of the body-building injection Deca-Durabolin
Popular cosmetic items from brands like Mamaearth
Routine Quality Testing by CDSCO
The action follows CDSCO’s April Non-Standard Quality (NSQ) report, which is part of the regulator’s monthly routine where it tests samples of pharmaceutical and cosmetic products to ensure they meet national standards. Batches that fail to pass the quality tests are listed as NSQ, and in serious cases, withdrawal or bans are issued.
Health authorities emphasize that this process is critical for patient safety and public health, as substandard products can pose significant risks, especially in the case of medications that are consumed by vulnerable populations.
Industry and Public Reaction
The ban has caused concern among doctors, pharmacists, and patients, especially as some of the listed products are regular household names. Industry experts believe the move will prompt companies to tighten their quality control mechanisms and could also lead to temporary shortages of certain medicines.
A senior CDSCO official stated, Public health is our priority. Any product that fails to meet the prescribed standards will not be allowed in the market, irrespective of the brand or frequency of use.
What Consumers Should Know:
Health professionals urge consumers not to panic, but to:
Check batch numbers of medicines and cosmetics they use.
Consult doctors or pharmacists if unsure about the safety of a product.
Avoid self-medication and purchase drugs only from authorized pharmacies.
With this decisive step, the CDSCO reiterates its commitment to ensuring the safety, efficacy, and quality of all medical and cosmetic products in the Indian market.
Antihistamines
A batch of the body-building injection Deca-Durabolin
Popular cosmetic items from brands like Mamaearth
Routine Quality Testing by CDSCO
The action follows CDSCO’s April Non-Standard Quality (NSQ) report, which is part of the regulator’s monthly routine where it tests samples of pharmaceutical and cosmetic products to ensure they meet national standards. Batches that fail to pass the quality tests are listed as NSQ, and in serious cases, withdrawal or bans are issued.
Health authorities emphasize that this process is critical for patient safety and public health, as substandard products can pose significant risks, especially in the case of medications that are consumed by vulnerable populations.
Industry and Public Reaction
The ban has caused concern among doctors, pharmacists, and patients, especially as some of the listed products are regular household names. Industry experts believe the move will prompt companies to tighten their quality control mechanisms and could also lead to temporary shortages of certain medicines.
A senior CDSCO official stated, Public health is our priority. Any product that fails to meet the prescribed standards will not be allowed in the market, irrespective of the brand or frequency of use.
What Consumers Should Know:
Health professionals urge consumers not to panic, but to:
Check batch numbers of medicines and cosmetics they use.
Consult doctors or pharmacists if unsure about the safety of a product.
Avoid self-medication and purchase drugs only from authorized pharmacies.
With this decisive step, the CDSCO reiterates its commitment to ensuring the safety, efficacy, and quality of all medical and cosmetic products in the Indian market.
Post a Comment